4-三氟甲基-7-氮杂吲哚 | 1092579-96-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 4-三氟甲基-7-氮杂吲哚
• 英文名称: 4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine
• CAS: 1092579-96-8
• 化学式: C₈H₅F₃N₂
• 分子量: 186.136
• InChiKey: YXLVZAOBNZQKEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-三氟甲基-7-氮杂吲哚 在 水 、 sodium hydride 、 potassium carbonate 、 间氯过氧苯甲酸 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 4.0h， 生成 1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-6-ol
  参考文献：
  名称：

  [EN] DNA POLYMERASE THETA INHIBITOR AND USE THEREOF
  [FR] INHIBITEUR D'ADN POLYMÉRASE THÊTA ET SON UTILISATION
  [ZH] 一种DNA聚合酶theta抑制剂及其应用

  摘要：

  本发明公开了一种DNA聚合酶theta抑制剂及其应用。本发明具体提供了如式（I）或式（II）所示的化合物，或其互变异构体、其立体异构体、前述任一者的药学上可接受的盐或前述任一者的溶剂合物。其对Polθ有较好的抑制作用。

  公开号：

  WO2023125918A1
• 作为产物：
  描述：

  1-tert-butyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 在 硫酸 作用下， 以 水 为溶剂， 以39%的产率得到4-三氟甲基-7-氮杂吲哚
  参考文献：
  名称：

  氟化吡咯并[2,3-b]吡啶和吡咯并[2,3-d]嘧啶核苷的合成

  摘要：

  为了合成新型ADAs（腺苷脱氨酶）和IMPDH（肌苷5'-单磷酸脱氢酶）抑制剂，5-氨基-1-叔丁基-1- H-吡咯-3-腈与氟化的1,3-反应研究了双亲电子试剂。开发了一种高效简便的氟化吡咯并[2,3- b ]吡啶的合成方法。的叔通过处理吡咯并吡啶或-pyrimidines用60％硫酸成功删除丁基保护基团并且在这之后由产物直接糖基化。 吡咯-胺-氟-吡啶-环化-亲电取代

  DOI：

  10.1055/s-0029-1216640

文献信息

• [EN] TRICYCLIC DLK INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE DLK TRICYCLIQUES ET UTILISATIONS ASSOCIÉES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016142310A1

  公开（公告）日：2016-09-15

  The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

  该发明涉及公式（I）的化合物及其盐，其中环A和R1-R2具有规范中定义的任何值。这些化合物和盐对于治疗由DLK介导的疾病有用。该发明还提供了包括公式（I）的化合物或其药学上可接受的盐的药物组合物，以及使用所述化合物、盐或组合物作为DLK抑制剂和治疗神经退行性疾病和疾病的方法。
• [EN] COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR<br/>[FR] COMPOSÉS ET MÉTHODES UTILISÉS POUR LA MODULATION DES KINASES ET INDICATIONS À CET EFFET
  申请人：PLEXXIKON INC

  公开号：WO2011063159A1

  公开（公告）日：2011-05-26

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

  描述了化合物及其盐、配方、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述化合物或其盐、配方、共轭物、衍生物、形式对至少一种Raf蛋白激酶具有活性。在某些方面和实施例中，所述化合物在抑制Ras突变细胞系增殖方面具有活性。还描述了使用这些方法来治疗疾病和病况，包括与B-Raf V600E突变蛋白激酶活性相关的疾病和病况，包括黑色素瘤、胶质瘤、胶质母细胞瘤、乳头状星形细胞瘤、结直肠癌、甲状腺癌、肺癌、卵巢癌、前列腺癌、肝癌、胆囊癌、胃肠间质瘤、胆道癌和胆管癌。还描述了使用这些方法来治疗与c-Raf-1蛋白激酶活性相关的疾病和病况，包括急性疼痛、慢性疼痛或多囊肾病。
• Facile Synthesis of Fluorinated Pyrrolo[2,3-b]pyridines
  作者：Ulrich Groth、Viktor Iaroshenko、Yan Wang、Thomas Wesch

  DOI：10.1055/s-0028-1087530

  日期：2009.2

  inhibitors the reaction of 5-amino-1-tert-butyl-1H-pyrrolo-3-carbonitrile with fluorinated 1,3-biselectrophiles was studied. An efficient and convenient synthetical approach to obtain fluorinated pyrrolo[2,3-b]pyridines was developed. tert-Butyl protecting group was successfully cleaved by treating of synthesized pyrrolo­pyridines with concentrated sulfuric acid.

  为了合成新型 ADA（腺苷脱氨酶）和 IMPDH（肌苷 5'-单磷酸脱氢酶）抑制剂，5-氨基-1-叔丁基-1H-吡咯并-3-甲腈与氟化 1,3-双亲电子试剂的反应是学习了。开发了一种高效便捷的合成方法来获得氟化吡咯并[2,3-b]吡啶。通过用浓硫酸处理合成的吡咯并吡啶，成功地裂解了叔丁基保护基团。
• SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS
  申请人：Blaney Jeffrey M.

  公开号：US20090005356A1

  公开（公告）日：2009-01-01

  Provided herein are substituted pyrrolopyridine heterocycles and substituted pyrazolopyridine heterocycles, pharmaceutical compositions comprising said heterocycles and methods of using said heterocycles in the treatment of disease. The heterocycles disclosed herein function as kinase modulators and have utility in the treatment of diseases such as cancer, allergy, asthma, inflammation, obstructive airway disease, autoimmune diseases, metabolic disease, infection, CNS disease, brain tumor, obesity, asthma, hematological disorder, degenerative neural disease, cardiovascular disease, or disease associated with angiogenesis, neovascularization, or vasculogenesis.

  本文提供了取代的吡咯吡啶杂环和取代的吡唑吡啶杂环，以及包含这些杂环的制药组合物以及使用这些杂环治疗疾病的方法。本文所披露的杂环可作为激酶调节剂，并在治疗癌症、过敏、哮喘、炎症、阻塞性呼吸道疾病、自身免疫疾病、代谢性疾病、感染、中枢神经系统疾病、脑肿瘤、肥胖症、哮喘、血液疾病、退行性神经疾病、心血管疾病或与血管生成、新生血管或血管生成有关的疾病中具有实用价值。
• Compounds and Methods for Kinase Modulation, and Indications Therefor
  申请人：Ibrahim Prabha N.

  公开号：US20110152258A1

  公开（公告）日：2011-06-23

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

  本文描述了化合物及其盐、制剂、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述的化合物或其盐、制剂、共轭物、衍生物、形式对至少一种Raf蛋白激酶具有活性。在某些方面和实施例中，所述的化合物对抑制Ras突变细胞系的增殖具有活性。还描述了使用这些化合物的方法来治疗与B-Raf V600E突变蛋白激酶活性相关的疾病和病症，包括黑色素瘤、胶质瘤、多形性胶质母细胞瘤、毛细胞星形胶质瘤、结肠直肠癌、甲状腺癌、肺癌、卵巢癌、前列腺癌、肝癌、胆囊癌、胃肠间质瘤、胆道癌和胆管癌。还描述了使用这些化合物的方法来治疗与c-Raf-1蛋白激酶活性相关的疾病和病症，包括急性疼痛、慢性疼痛或多囊肾病。